logo
Scientists gobsmacked by never-seen footage of earth rupturing during Myanmar quake

Scientists gobsmacked by never-seen footage of earth rupturing during Myanmar quake

Yahoo18-05-2025

When you watch the video below, don't get distracted by the cracking concrete or the metal gate rocking back and forth. Keep your eyes focused on the right side of the screen, where you will see an astonishing sight — one that earthquake scientists say has never been caught on camera before.
The video was captured by a surveillance camera on March 28, when a violent earthquake struck the southeast Asian country of Myanmar — causing widespread damage as far away as Bangkok in neighbouring Thailand, and killing some 3,700 people, according to Myanmar's ruling military junta.
The footage shows the moment the 7.7 magnitude quake caused the land on one side to thrust forward with a powerful jolt, as a rupture ripped opened the earth for 460 kilometres along the Sagaing Fault.
"My jaw hit the floor," said Wendy Bohon, an earthquake geologist and science communication specialist in Sacramento, Calif., when she saw it.
WATCH | Video captures land mass shifts, earth ruptures during Myanmar quake:
Satellite imagery and other data had already helped scientists determine the extent of the rupture and approximately how much the earth moved. But seeing such a dramatic shift of the landscape in action is a first for scientists like Bohon, and may prove to be an invaluable tool in understanding the type of earthquake that ravaged Myanmar.
"We have computer models of it. We have laboratory models of it. But all of those are far less complex than the actual natural system. So to see it actually happening was mind-blowing," she told CBC News.
Why the earth shifted so powerfully
"I keep going back and watching it," said geologist Judith Hubbard, an assistant professor at Cornell University's department of Earth and atmospheric sciences.
"It's really kind of staggering to see a fault slide in real time, especially for someone like me, who has spent years studying these things, but always from more remote kinds of data, like offsets after the fact or data recorded by sensors," she said in an email interview.
The Sagaing Fault runs some 1,400 kilometres, between the Indian and Eurasian plates, right through Myanmar and into the Andaman Sea. It's a strike-slip fault, meaning that when an earthquake happens, the land mass on one side of the fault slides past the other.
Researchers with NASA's Jet Propulsion Lab used satellite and radar data to determine that the earthquake caused a horizontal displacement up to six metres in some locations along the fault. The Geospatial Information Authority of Japan made similar observations.
Scientists like Hubbard say there is "compelling evidence" it was a supershear earthquake.
That's when the speed of the rupture, which is generally slower-moving, travels faster than seismic waves that the earthquake produces, which can travel up to six kilometres per second.
The video appeared May 11 on a YouTube channel called 2025 Sagaing Earthquake Archive, which has been curating social media videos and security camera footage since the quake struck.
According to a Facebook post linked in the caption, the video was from a camera at a power facility in Tha Phay Wa. That's in the township of Thazi, some 110 kilometres south of the city of Mandalay, and close to the epicentre of the quake and its 6.7 magnitude aftershock.
A Google Maps satellite view of the area shows a power facility located in this area and close to the Saigang Fault.
Hubbard said that watching the video, it doesn't look like the quake was supershear at this location, because you see the seismic waves hit and the terrain shaking before the rupture occurs. But it's possible it was happening at supershear speed elsewhere along the fault.
She said this video offers her and other earthquake scientists "a really striking observation."
"We don't tend to have instruments right along the fault. They are often disrupted by shaking," she said.
This happened right there in front of their eyes, on video, which means they don't only have to rely on analyzing and interpreting complicated recordings and data to determine what happened on the ground.
WATCH | Myanmar earthquake rescue, relief efforts hindered by lack of supplies, civil war:
How to tell what we're seeing is real
Bohon said there's little doubt the video is real and she doesn't believe it's been altered or fabricated in any way.
She said there are finer details in the background that you would have to pay close attention to, or that AI tools wouldn't know to generate — such as a bird flying away as the shaking begins about 12 seconds into the video, and power lines straining and eventually causing a transmission tower to buckle a few seconds later.
"There's also another kind of more subtle thing," Bohon said. "It's called the geomorphology, the shape of the surface of the earth."
Earthquakes, she explained, change the landscape and move hills and rivers.
She pointed to the small hill in the background of the CCTV footage, situated along the fault, that thrusts forward.
"That hill in the background, that you see move towards the camera," she said. "If you look at it, it's kind of long and linear, and then it just cuts off right about where the fault is."
She said that if you can view the location using satellite imagery, you could look to see where the other half of that hill is in relation to the portion that moved forward in the quake.
The observations Bohon made to verify what she was seeing in the video also told her a lot about the earthquake itself and that this kind of footage has "tremendous scientific value."
She said that despite the violent shaking and and shifting of the earth, it was interesting to see that small structures were relatively unscathed considering the force of the quake.
"Watching the destruction in the nearground and watching it in the background, and then even further away, was a really interesting look into how earthquakes impact things right next to the fault and at varying degrees away from the fault itself," she said.
As "devastating and horrific" as earthquakes like the one in Myanmar can be, Bohon said they always present a learning opportunity that can hopefully be used to improve safety and protect lives.
While this footage is a first, Bohon expects there will be more to come because of the prevalence of CCTV and other types of cameras that are capturing video around the clock and from multiple angles.
WATCH | Rescue crews in Myanmar, Thailand work tirelessly to find quake survivors in rubble:

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

Yahoo

timean hour ago

  • Yahoo

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

Yahoo

timean hour ago

  • Yahoo

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The Indian pilot set for a historic space journey on Axiom-4
The Indian pilot set for a historic space journey on Axiom-4

Yahoo

time3 hours ago

  • Yahoo

The Indian pilot set for a historic space journey on Axiom-4

The Axiom Mission 4 (Ax-4), set to take off from Nasa's Kennedy Space Center in Florida next week, will be piloted by an Indian as it soars towards the International Space Station (ISS). Group Captain Shubhanshu Shukla of the Indian air force is among the four-member multi-country crew of Ax-4 that will be spending two weeks on the ISS. The flight, scheduled for 10 June at 08:22 EDT (12:22GMT; 17:52IST), has generated a huge interest in India as Group Captain Shukla will only be the second Indian ever to travel to space and the first to visit the ISS. The trip comes 41 years after cosmonaut Rakesh Sharma became the first Indian to fly to space aboard a Russian Soyuz in 1984. He spent nearly eight days there. Ax-4 is led by former Nasa astronaut Peggy Whitson - a space veteran who has been commander of ISS twice, spent hundreds of days in space and done 10 space walks. The team also includes Slawosz Uznanski-Wisniewski from Poland and Tibor Kapu from Hungary - just like the Indian astronaut, they will also be taking their countries back to space after more than four decades. Experts say the pilot's role is key, as he would serve as second-in-command to the mission commander, assisting with spacecraft operations during launch, docking, undocking and return to Earth. The astronauts, who have been in quarantine since 25 May to prepare for the trip, addressed a press conference on Tuesday night where they showed-off Joy - a small, white toy swan they said would be "the fifth crew member" on Ax-4. "We are good for the launch, we have completed all the training and the team has bonded well," Commander Whitson said. Describing the past year as "nothing short of transformative" for him, Group Captain Shukla said he did not have words to describe his excitement. "It has been an amazing journey so far, but the best is yet to come," he said. "As I go into space, I carry not just instruments and equipment, I carry hopes and dreams of a billion hearts. "I request all Indians to pray for the success of our mission," he added. The 39-year-old was among four Indian air force officers shortlisted last year to travel on the country's first-ever human space flight, scheduled for 2027. The Gaganyaan mission aims to send three astronauts to an orbit of 400km and bring them back after three days. India has also announced ambitious plans to set up a space station by 2035 and send an astronaut to the Moon by 2040. India's space agency Isro has been carrying out a number of tests to prepare for Gaganyaan. In December, it plans to send a female humanoid robot to space as part of the tests. So, officials say the weekend's mission comes as a "unique exciting opportunity" for Isro and has generated a lot of interest in India. The trip to ISS aboard Ax-4 - a commercial flight operated by Houston-based private company Axiom Space - is a collaborative effort between Nasa, Isro and European Space Agency (Esa). Sunday's flight will be launched using the SpaceX Crew Dragon capsule on a Falcon 9 rocket. Isro, which has paid 5bn rupees ($59m; £43m) to secure a seat for Group Captain Shukla and his training, says the experience he will gain during his trip to the ISS will help India immensely. "The benefit we will get from this mission is phenomenal in terms of the training, exposure to the facilities and the experience of jointly conducting experiments in space," Isro Chairman V Narayanan recently said. Sudeesh Balan, Isro project director, said Group Captain Shukla had been training since August last year. "He's undergone rigorous training, including physical and psychological assessments, to prepare for the journey." Born on 10 October 1985 in the northern city of Lucknow, Group Captain Shukla joined the Indian air force as a fighter pilot in 2006. According to Axiom Space, he has over 2,000 hours of flying experience and has flown MiGs, Sukhois, Dorniers, Jaguars and Hawks. His sister Shuchi Mishra, however, told the BBC that his entry into the air force was "accidental". "When he was 17 and in high school, his friend got a form to apply to the National Defence Academy. But this friend was slightly overage so he was not qualified. Not wanting to waste the form, Shubhanshu filled it up," Ms Mishra said. "He was selected - and has never looked back." Ms Mishra says their family "is thrilled as one of ours has been chosen out of India's 1.4 billion people" for this mission. "We all feel so privileged and proud that he's a part of our family and that we've been a part of his journey." Her brother, she says, is undertaking this journey for his country - for the next generation. "He always tells people to dream big, to do something for the nation. We are hoping that his trip will inspire the next generation." Besides piloting the mission, the Indian astronaut will have a busy schedule during his time on ISS. Considering the huge interest in the flight, Isro has said they are organising events for him to interact with Indian students and answer their questions while floating in space. "We believe it will motivate our young minds to become passionate about space tech," Mr Balan said. But most of the time, the four-member crew will be conducting 60 scientific experiments, seven of which come from India. Former Nasa scientist Mila Mitra says Isro's experiments will help improve our understanding of space and its effects on biology and micro-gravity. One of the key experiments, she explains, will investigate the impact of spaceflight on six varieties of crop seeds. "This project aims to help understand how crops may be grown in space for future exploration missions. After the mission, seeds will be grown for multiple generations and plants showing preferred traits will be selected for genetic analyses." Another Isro experiment involves growing three strains of microalgae which could be used as food, fuel or even in life support systems and this will help identify the most suitable ones for growing in microgravity, she says. The Isro projects would also investigate how tardigrades - micro-animals on Earth that can survive extreme environments - would fare in space. "The project will examine the revival of dormant tardigrades, count the number of eggs laid and hatched during a mission, and compare space-flown versus ground control populations," Ms Mitra says. The other experiments aim to identify how muscle loss occurs in space and how it can be treated; and the physical and cognitive impact of using computer screens in microgravity. "The research will study how gaze fixation and rapid eye movements are affected by being in space, and how this may affect an astronaut's stress and wellbeing. The results could influence future spacecraft computer design and interaction," she says. Follow BBC News India on Instagram, YouTube, X and Facebook.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store